Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review presents standardized methods for assessing and tracking hair loss in alopecia areata but reports no clinical results, with the authors noting time limitations in clinical practice.

This article reviews comprehensive surveys on the prevalence and impact of skin disease in resource-poor countries, but reports no new clinical results; it highlights challenges such as health literacy and service access.

This study found that in dermatological patients, poorer quality of life was associated with being younger, single, having a low income, one skin disease, and longer duration of the condition.

This review discusses the significant burden of disease and psychosocial implications associated with alopecia, highlighting its comorbidities and the impact on quality of life despite being viewed traditionally as an aesthetic concern, but reports no clinical results.

This chapter reviews advancements in nanocarriers for delivering antipsoriatic drugs to improve skin targeting and therapeutic efficacy, reporting no new experimental results.

This review highlights current knowledge about quality of life assessment in alopecia areata, noting limited use of existing instruments and a need for further validation.

This review discusses the importance of recognizing and treating psychiatric conditions in dermatology patients, offering practical recommendations for dermatologists to manage psychocutaneous diseases effectively, but reports no new clinical results.

This study highlights the significant psychological impact of alopecia areata, emphasizing the reciprocal relationship between the disorder and psychiatric issues, and underscores the importance of identifying patients needing additional psychological support, especially women, young individuals, and those with severe alopecia or previous psychiatric history.

Most people with alopecia areata have nail changes, which are common but don't greatly affect their quality of life.

In this study, the severity of pediatric alopecia areata was found to decrease the quality of life for both patients and their families while increasing the overall burden.

This study found that dermatological treatments significantly reduce health-related quality of life among patients with various skin conditions, suggesting that the burden of these therapies should be considered in treatment planning and development.

This study found that hair transplant surgery significantly improves health utility scores compared to untreated androgenetic alopecia in both men and women, as perceived by laypeople.

This study reviewed the physiological and psychological impacts of acne vulgaris, highlighting its complex interactions with endocrine issues, sebum production, and immune response, while suggesting that a multidisciplinary approach can inform future treatments and improve quality of life for those affected.

This study developed the Alopecia Areata Patient Priority Outcome (AAPPO), a new tool designed to measure and capture the symptoms and impacts of alopecia areata that matter most to patients.

This study found that daily use of an emollient PLUS containing ADE-G1 significantly reduced xerosis severity and improved quality of life in cancer patients, regardless of their initial xerosis severity or cancer treatment.

This study identified six key concerns, including self-consciousness and physical symptoms, among patients with cutaneous lupus erythematosus that should be considered in quality-of-life assessments.

This study reports that patients with androgenetic alopecia had lower quality of life scores across all measured domains compared to controls, with disease severity worsening the impact, particularly socially for those under 30.

This review found that commercial influences may affect how male baldness is represented as a disease and how treatment options are presented, often omitting limitations.

Estrogen deficiency, like after menopause or certain surgeries, leads to faster skin aging and health issues.

This study analyzed watercress oil and confirmed its phytochemical profile, UV absorption properties, and potential efficacy for hair growth, supporting traditional hot oil applications.

This study observed that hair characteristics significantly impact daily life, self-image, and well-being, varying by gender, ethnicity, and country, suggesting a need for interventions to address these psychological and social effects.

This study found that ritlecitinib improved patient-reported outcomes related to hair growth in individuals with alopecia areata, with some experiencing clinically meaningful hair regrowth, although changes in emotional symptoms and activity limitations were minimal and similar across treatment groups.

This analysis examines acne vulgaris using an integrative approach, highlighting its links with psychopathology, lifestyle, and diet, but reports no new results.

This study established consensus criteria for classifying alopecia areata severity, aiding clinicians in accurate diagnosis and treatment planning.

This article discusses the emerging field of supportive oncodermatology, which collaborates between oncology and dermatology to address skin-related side effects of cancer treatments, and reports no new clinical results.

This article discusses the creation of Alopecia Areata Uniform Protocols by the National Alopecia Areata Foundation to standardize clinical trials for alopecia areata treatments and reports no new results.

This review discusses approaches to diagnosing and managing cutaneous manifestations of lupus erythematosus and reports no new clinical results.

This study indicates that the EQ-5D-5L may not effectively capture the burden of alopecia areata on patients' health-related quality of life, and suggests that alternative measures might better assess treatment benefits related to hair regrowth.

This review concluded that baricitinib and other oral JAK inhibitors have the most robust evidence supporting their use in treating severe alopecia areata in adults, compared to other less-evaluated treatments.

The BASP classification helps predict patient behavior and improve treatment for hair loss.